USDA is an equal opportunity provider, employer and lender. To file a complaint of discrimination, write: USDA, Director, Office of Civil Rights, 1400 Independence Avenue, SW, Washington, DC 20250-9410 or call 800-795-3272 (voice), or 202-720-6382 (TDD).
Recall Release
CLASS I RECALL HEALTH RISK: HIGH
Congressional and Public Affairs Benjamin A. Bell 202-720-9113
FSISpress@usda.gov FSIS-RC-019-2022
YUMEI FOODS USA, INC. RECALLS INELIGIBLE SILURIFORMES
PRODUCTS IMPORTED FROM CHINA
WASHINGTON, June 13, 2022 – Yumei Foods USA, Inc., a City of Industry, Calif. establishment, is recalling approximately 9,370 pounds of imported Siluriformes products. The products were imported from the People’s Republic of China, a country ineligible to export processed Siluriformes products to the United States, the U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) announced today.
The following products are subject to recall, regardless of the product date [View Labels]:
13.051 oz. (370g) plastic packages containing “FISH FILLET WITH SPICY SOUP” Freeze Dried Technology Fish. No Preservative.
12.35 oz. (350g) plastic packages containing “FISH FILLET WITH PICKLED SOUP” Freeze Dried Technology Fish. No Preservative.
The products do not bear an establishment number nor a USDA mark of inspection. These items were shipped to retail and wholesale locations nationwide.
The problem was discovered during a routine FSIS surveillance activity of imported products. China is eligible to import raw Siluriformes products into the United States, but not processed or ready to eat Siluriformes products.
There have been no confirmed reports of adverse reactions due to consumption of these products. Anyone concerned about a reaction should contact a healthcare provider.
FSIS is concerned that consumers may still be in possession of the product. Consumers who have purchased these products are urged not to consume them. These products should be thrown away or returned to the place of purchase.
FSIS routinely conducts recall effectiveness checks to verify recalling firms notify their customers of the recall and that steps are taken to make certain that the product is no longer available to consumers. When available, the retail distribution list(s) will be posted on the FSIS website at www.fsis.usda.gov/recalls.
Consumers and members of the media with questions about the recall can contact Jiazhuo Xie, Owner, Yumei Foods USA, Inc., at 626-270-5010.
Consumers with food safety questions can call the toll-free USDA Meat and Poultry Hotline at 1-888-MPHotline (1-888-674-6854) or live chat via Ask USDA from 10 a.m. to 6 p.m. (Eastern Time) Monday through Friday. Consumers can also browse food safety messages at Ask USDA or send a question via email to MPHotline@usda.gov. For consumers that need to report a problem with a meat, poultry, or egg product, the online Electronic Consumer Complaint Monitoring System can be accessed 24 hours a day at https://foodcomplaint.fsis.usda.gov/eCCF/.
Class I This is a health hazard situation where there is a reasonable probability that the use of the product will cause serious, adverse health consequences or death.
Class II This is a health hazard situation where there is a remote probability of adverse health consequences from the use of the product.
Class III This is a situation where the use of the product will not cause adverse health consequences.
CONTACT: USDA FSIS USDA Food Safety and Inspection Service press@fsis.usda.gov
The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) recently adopted a positive opinion that recommended the approval of AbbVie's (NYSE: ABBV) Rinvoq for what would be its fifth indication in that market. This would be to treat patients with moderate-to-severe ulcerative colitis who had an inadequate response to conventional therapies or biologic agents. A decision for Rinvoq as a treatment for moderate-to-severe ulcerative colitis patients from the European Commission is expected in the third quarter of this year.
While the daily average of new COVID-19 cases have settled back into a low-100K range that has lasted for about seven weeks, hospitalizations took their first dip since mid-April and deaths ticked up to a 2 1/2-month high.
At the heart of the deal is the U.S.-based company's early stage experimental treatment for a form of Non-Hodgkin's lymphoma, a type of cancer that involves the growth of abnormal white blood cells that can lead to the emergence of tumours. The Anglo-Swedish drugmaker - whose key blood cancer drug Calquence generated sales of more than $1.2 billion last year - plans to acquire all outstanding equity of TeneoTwo for an upfront payment of $100 million, with additional milestone-related payments of up to $1.17 billion. TeneoTwo's experimental drug, TNB-486, belongs to a class of bispecific antibodies that are engineered to redirect the immune system to recognise and kill cancer cells.
U.S. Covid-19 infections are surging, though hospitalizations remain low. The FDA has already asked for boosters that specifically target BA.4 and BA.5.
A federal judge found that the plaintiffs, Cabell County and the city of Huntington, didn’t show that actions by McKesson, AmerisourceBergen and Cardinal Health caused the crisis.
Britain is proposing a new law that will require social media companies to proactively tackle disinformation posted by foreign states such as Russia, the government said on Monday. The law would tackle fake accounts on platforms such as Meta's Facebook and Twitter that were set up on behalf of foreign states to influence elections or court proceedings, the government said. The law is likely to be passed during this parliamentary session through an amendment to link the National Security Bill and Online Safety Bill, both of which are in the government's current programme.
Omicron subvariants BA.4 and BA.5 are driving another COVID-19 surge in the US, virus experts warn. "Our data suggest that these new Omicron subvariants will likely be able to lead to surges of infections in populations with high levels of vaccine immunity as well as natural BA.1 and BA.2 immunity," says Dr. Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston. "However, it is likely that vaccine immunity will still provide subst
Human longevity is of great interest to researchers, who have uncovered a number of risk factors for a limited lifespan but have yet to find a crystal ball that can pinpoint how long a person has to live. But Brazilian scientists say one simple physical test may indicate whether you're at increased risk of dying in the next 10 years. Read on to find out more—and to ensure your health and the health of others, don't miss these Sure Signs You've Already Had COVID. 1 This Test Could Predict Your Lo
In an essay written for Vogue, Halsey shared details of how an abortion saved their life after having suffered three miscarriages before her 24th birthday. “One of my miscarriages required ‘aftercare,’ a gentle way of saying that I would need an abortion,” Halsey wrote. “My body could not terminate the pregnancy completely on its own […]
Though the United States appears to be coming out of the worst of the pandemic, COVID-19 isn't going away any time soon. And there remains the continued risk of another surge as more states relax...
Ten days after Roe v. Wade was overturned, Colorado is seeing more and more people coming to the state for abortions. Colorado is considered a safe haven state for people seeking an abortion as it remains legal at all stages of pregnancy.
Photo Illustration by The Daily Beast / GettyThe more times you catch COVID, the sicker you’re likely to get with each reinfection. That’s the worrying conclusion of a new study drawing on data from the U.S. Veterans Administration.Scientists stressed they need more data before they can say for sure whether, and why, COVID might get worse the second, third, or fourth time around. But with more and more people getting reinfected as the pandemic lurches toward its fourth year, the study hints at s
As of now, there is no known cure for dementia or the diseases that most commonly cause it, such as Alzheimer's and Lewy body dementia. Access to treatment and management options make it crucial to catch the early symptoms of these devastating conditions, which affected nearly six million Americans in 2020—with that number expected to nearly triple to 14 million people in the next four decades, according to the Centers for Disease Control and Prevention (CDC)."Memory problems are typically one o
Yahoo Finance
Yahoo Finance Plus 
